GLP-1 medications copy a gut hormone called glucagon-like peptide-1 that your body releases after a meal. That signal nudges the pancreas to release insulin, slows how fast the stomach empties, and quiets appetite. The result is lower blood sugar and, for most people, weight loss. These drugs treat type 2 diabetes, obesity, or both, and they come as weekly injections and, more recently, daily pills. This guide explains the differences in plain terms.
What is a GLP-1 medication doing in the body?
The class works by activating the GLP-1 receptor, and a good review of the biology describes the effect as glucose-dependent, meaning insulin rises mainly when blood sugar is high. That design is why these drugs rarely cause dangerous low blood sugar on their own. The same signaling reaches the brain’s appetite centers and the gut’s motility, which is the practical reason people feel full sooner and eat less. The mechanics of how these receptors translate into treatment are laid out clearly in the published mechanism review.
Some newer drugs go further and activate a second receptor, GIP, alongside GLP-1. The idea that combining the two could improve results traced back to early work on tirzepatide, described in the original discovery and proof-of-concept paper. In practice, the dual mechanism has tended to produce larger weight and glucose effects than single-receptor drugs, though direct comparisons between separate trials should be read with caution.
See also: Living Your Best Life: Embracing a Vibrant Lifestyle Journey
Which GLP-1 medications actually exist?
The names matter because they are not interchangeable. Semaglutide is sold as Ozempic and Rybelsus for diabetes and as Wegovy for weight management. Tirzepatide, the dual GIP and GLP-1 agonist, is sold as Mounjaro for diabetes and Zepbound for weight management. Liraglutide is an older daily injection. Orforglipron, brand name FOUNDAYO, is a daily oral small-molecule agonist that reached FDA approval in 2026 for weight management. Retatrutide, a triple-receptor drug, remains investigational and is not approved.
People researching the class often want a single reference list of every molecule and its brands, and resources that catalog the GLP-1 agonist drugs can be a useful starting point before a conversation with a prescriber. Just remember that approval status and indication vary drug by drug.
How do the main options compare?
| Drug (molecule) | Receptors | Form | Approved use |
|---|---|---|---|
| Semaglutide | GLP-1 | Weekly injection or daily pill | Type 2 diabetes and weight management |
| Tirzepatide | GIP and GLP-1 | Weekly injection | Type 2 diabetes and weight management |
| Liraglutide | GLP-1 | Daily injection | Type 2 diabetes and weight management |
| Orforglipron | GLP-1 | Daily pill | Weight management, approved 2026 |
| Retatrutide | GIP, GLP-1, glucagon | Injection | Investigational, not approved |
What is the story with the oral pill?
The injection has been the main barrier for a lot of people. Orforglipron changes that because it is a small molecule that survives being swallowed, unlike the peptide drugs. Early clinical work published in 2023 showed meaningful weight reduction from the daily oral agonist in adults with obesity, and a later obesity-treatment study confirmed the effect at scale in the phase 3 obesity trial. The regulatory milestone itself is documented in the first-approval summary.
A pill is genuinely convenient, and for needle-averse patients that convenience is not trivial. It is not magic, though. It carries the same nausea, reduced appetite, and gastrointestinal side effects as the rest of the class, and it is still a prescription drug that needs monitoring. Convenience is a reason to consider it, not a reason to assume it is gentler.
Who are these drugs actually for?
Guidelines are more specific than the marketing suggests. A 2025 clinical practice guideline update on pharmacotherapy for obesity in adults frames these medications as a treatment for a chronic condition rather than a short cosmetic course. Earlier guidance from the AGA on pharmacological interventions for adults with obesity reached a similar conclusion, favoring the most effective agents for people who meet the criteria.
What counts as clinical obesity is itself being redefined. A 2025 consensus paper on the definition and diagnostic criteria of clinical obesity argued for moving past body mass index alone toward measures of actual organ and tissue impairment. That shift matters because it changes who a prescriber sees as a candidate. There is also growing interest in these drugs beyond weight and glucose, including in liver disease, reflected in the EASL-EASD-EASO guidelines on metabolic dysfunction-associated steatotic liver disease.
Where do compounded versions fit?
During shortages, compounded semaglutide and tirzepatide became common through telehealth. These are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule as the brand, but they have not been through the approval process that generated the published trial evidence, and quality can vary by pharmacy. That is a real difference in oversight, not a marketing quibble.
Named telehealth routes cover this space in different ways. Ro, Hims and Hers, and Henry Meds prescribe through their own clinicians, LillyDirect and NovoCare sell branded product from the manufacturers, and physician-supervised services such as FormBlends offer compounded options with prescribing handled by a licensed clinician. If a branded, self-pay path is affordable, the honest advice is to prefer the approved product. Compounded medicine is a reasonable option in specific situations, but it should sit with a prescriber who knows the case, not be chosen on price alone.
Key takeaways
- GLP-1 drugs mimic a gut hormone to lower blood sugar and reduce appetite.
- Dual-receptor drugs like tirzepatide add a second target and often larger effects.
- Names are not interchangeable, and each has its own approved use.
- Orforglipron brought an approved daily pill to weight management in 2026.
- Compounded versions are not FDA-approved and belong with a prescriber’s judgment.
Frequently asked questions
What does GLP-1 actually stand for?
GLP-1 is glucagon-like peptide-1, a gut hormone released after eating. The medications in this class copy its signal, which prompts insulin release, slows stomach emptying, and reduces appetite. That combined effect is why they lower blood sugar and body weight.
Are all GLP-1 medications the same?
No. Some act only on the GLP-1 receptor, while others also hit the GIP receptor. Some are weekly injections, some are daily pills. Approvals differ too, with certain drugs cleared for type 2 diabetes, others for weight management, and a few for both.
Is there a GLP-1 pill?
Yes. Oral semaglutide has existed for diabetes, and orforglipron, a daily small-molecule pill, was FDA-approved in 2026 for weight management. A pill removes the injection barrier but is still a prescription medicine with the same class-wide side effects.
Is compounded GLP-1 medication the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule, but they have not gone through the approval process that produced the trial evidence for the branded drugs.
Who are GLP-1 medications meant for?
Broadly, adults with type 2 diabetes or with obesity, sometimes defined with a related health condition. Guidelines set body mass index thresholds and clinical criteria, and a prescriber decides whether the medication fits the individual case.
